Trial Profile
A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adult patients with EGFR wild-type, ALK rearrangement negative locally advanced/metastatic non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2022
Price :
$35
*
At a glance
- Drugs Capmatinib (Primary) ; Spartalizumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 02 Sep 2021 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 16 Oct 2020 Status changed from active, no longer recruiting to completed.
- 10 Oct 2020 This trial has been completed in Netherlands.